Evaluation of colchicine in treatment of coronavirus

Evaluation of the therapeutic effect of colchicine plus chloroquine in comparison with chloroquine in patients with COVID-19

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200418047126N1

Enrollment

100

Registered

2020-05-14

Start date

2020-05-04

Completion date

Unknown

Last updated

2020-06-15

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary infection of COVD19. Coronavirus infection, unspecified

Interventions

Intervention 1: Intervention group: A 1 mg tablet of colchicine daily for 10 days. Intervention 2: Control group: A placebo tablet daily for 10 days.

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: Positive PCR for COVID19

Exclusion criteria

Exclusion criteria: Sensitivity of patients to any medication that is in the regimen Renal failure Heart disease Pregnancy

Design outcomes

Primary

Measure	Time frame
Hospitalization outcome. Timepoint: Last day of hospitalization in the section. Method of measurement: Calendar.;Fever cessation. Timepoint: Before hospitalization and 1, 3, 5, 7 days after hospitalization. Method of measurement: calendar.;Hospitalization time. Timepoint: First and last day of hospitalization. Method of measurement: Calendar.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFarhad Pourfarzi

Ardabil University of Medical Sciences

farhad.pourfarzi@gmail.com+98 45 3353 4798

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026